Score Overview
Explore the 2021 public Archive ranking →
Where Tekla Life Sciences Investors has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- HQL
2009: 71.9% · 2021: 41.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 18.90 | — |
1 Year2025-09-26 | $ 13.17 | 43.56% |
5 Years2021-09-28 | $ 11.80 | 60.16% |
10 Years2016-09-28 | $ 7.14 | 164.85% |
20 Years2006-09-28 | $ 2.16 | 8x |
30 Years1996-09-27 | $ 0.82 | 23x |
All Time1992-05-04 | $ 0.82 | 22x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1992-05-04 |
|---|---|---|---|---|---|---|---|
| Price | $ 18.90 | $ 13.17 | $ 11.80 | $ 7.14 | $ 2.16 | $ 0.82 | $ 0.82 |
| Return | — | 43.56% | 60.16% | 164.85% | 8x | 23x | 22x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2025 | $ 86M | $ 85M | $ 75.54K |
| 2024 | $ 86M | $ 85M | $ 1.00 |
| 2023 | $ 23M | $ 22M | $ 15M |
| 2022 | -$ 103M | -$ 104M | $ 445.00 |
| 2021 | $ 65M | $ 64M | $ 990.00 |
| 2020 | $ 124M | $ 123M | $ 4M |
| 2019 | -$ 69M | -$ 70M | $ 1M |
| 2018 | $ 1M | $ 28M | $ 40.00 |
| 2017 | $ 69M | $ 68M | $ 615.31K |
| 2016 | $ 6M | -$ 11M | $ 9M |
| 2015 | $ 1M | $ 40M | $ 403.00 |
| 2014 | $ 876.79K | $ 89M | $ 2.34K |
| 2013 | $ 516.76K | $ 84M | $ 36.58K |
| 2012 | $ 2M | $ 77M | $ 689.00 |
| 2011 | $ 570K | $ 37M | |
| 2010 | $ 1M | $ 10M | |
| 2009 | $ 460K | -$ 21M | $ 5M |
| 2008 | $ 1M | $ 60M | |
| 2007 | $ 2M | $ 50M | |
| 2006 | $ 2M | -$ 21M | |
| 2005 | $ 890K | $ 44M | |
| 2004 | $ 320K | $ 7M | $ 700K |
| 2003 | $ 610K | $ 38M | $ 1M |
| 2002 | $ 940K | -$ 50M | $ 100K |
| 2001 | $ 1M | -$ 95M | $ 400K |
| 1998 | $ 140K | -$ 30M | |
| 1997 | $ 320K | $ 15M | $ 100K |
| 1996 | $ 420K | $ 21M | $ 200K |
Tekla Life Sciences Investors fundamental performance
Between 2020 and 2025, revenue declined from $ 124M to $ 86M and net income declined from $ 123M to $ 85M. Revenue increased in 2 of those 5 years; net income in 3.
Across Tekla Life Sciences Investors's full reported history, from 1996 to 2025, revenue grew from $ 420K to $ 86M and net income grew from $ 21M to $ 85M. Revenue increased in 48% of the years measured; net income in 56%.
Tekla Life Sciences Investors currently holds a 20-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Membership
Continue HQL’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
